Skip to content

Evaluation the effect of colchicine on acute myocardial infarction

Evaluation the effect of colchicine on the outcome and noreflow of blood in the coronary arteries in patients undergoing primary percutaneous coronary intervention in patients with acute myocardial infarction

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230620058546N1
Enrollment
120
Registered
2023-08-09
Start date
2023-06-25
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute heart attack. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: 2 mg of oral colchicine as a loading dose (two tablets) then 0.5 mg (half a tablet) of colchicine twice a day (every 12 hours) for 30 days. Intervention 2: Control

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who have ST elevation myocardial infarction and are candidates for primary percutaneous intervention

Exclusion criteria

Exclusion criteria: Hemodynamic instability liver failure kidney failure history of blood disease chronic colchicine use

Design outcomes

Primary

MeasureTime frame
Investigation of TIMI flow rate in coronary arteries after stent placement in acute myocardial infarction patients. Timepoint: After the intervention and at the beginning of the study. Method of measurement: Judgment by cardiologist after angiography.

Secondary

MeasureTime frame
Examination of the small amount of TROPONIN. Timepoint: at admission and 24 and 48 hours later. Method of measurement: in the laboratory by quantitative troponin kits.;Investigating the increase of CRP. Timepoint: at the beginning of hospitalization and 48 hours later. Method of measurement: Measurement by quantitative kits in the laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOzra Kahourian

Oroumia University of Medical Sciences

kahourian.ozra@gmail.com+98 44 3235 7473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026